Supplement: Oncology November 2011
The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals
The Future of Treatment for Patients With Relapsed/Refractory Multiple MyelomaThe supplement and associated publication costs were funded by Onyx Pharmaceuticals
The goal of this supplement is to present a comprehensive overview of the major current and emerging treatment options for patients with relapsed and/or refractory multiple myeloma, with particular focus on proteasome inhibitors and immunomodulatory drugs, along with other emerging agents (eg, histone deacetylase inhibitors, heat shock protein inhibitors, and monoclonal antibodies). As the treatment landscape has evolved, it has become readily apparent that the available therapies have different tolerability profiles depending on patient and disease characteristics.
